
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

BenevolentAI Ltd inks US$594m partnership with Merck KGaA
Under the licence agreement, BenevolentAI will identify and develop new compounds against three targets provided by Merck through hit identification...

Solar Foods raises €8m in Series B financing
Solar Foods Oy has raised €8m (US$8.8m) from retail investors in Finland. The Series B round was led by Finland’s Springvest Oy, existing...

SpliceBio has made up a US $216m alliance with Spark Therapeutics
Under a globally exclusive licence option agreement with Roche AG, SpliceBio secures an upfront payment, opt-in and milestone payments up to $216m...

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica PLC, and Institut Mérieux have entered exclusive negotiations for the acquisition of ABL Europe Inc. This move is set to solidify...

SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Lonza's centre of excellence, Synaffix B.V. (Amsterdam, The Netherlands) has entered a licensing agreement with immuno-oncology specialist SOTIO...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...